Recent Updates
Recently added Catalysts
OBIO Positive Sentiment Score: 70/100

Orchestra BioMed to Participate in Upcoming Investor Conferences

Key Takeaway: Orchestra BioMed Holdings, Inc. has announced its participation in several investor conferences in March 2024. The company will present at the Oppenheimer Annual Healthcare MedTech and Services Conference on March 12 and engage in a fireside chat at the Barclays Global Healthcare Conference on March 14. These events are part of Orchestra BioMed's strategy to enhance investor relations and share updates on their high-impact biomedical technologies.

Market Sentiment Analysis

POSITIVE FACTORS

  • Orchestra BioMed is actively engaging with investors through multiple conferences.
  • The company has scheduled a corporate presentation and fireside chat which can increase visibility.
  • The management is available for one-on-one meetings, indicating openness to shareholder engagement.

Full Press Release Details

NEW HOPE, Pa., March 07, 2024 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, “Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partnerships, today announced that company management will present and be available for one-on-one meetings at multiple conferences throughout March 2024.
Details on the presentations are shown below.
Oppenheimer Annual Healthcare MedTech and Services Conference
Format: Corporate Presentation
Date: March 12, 2024
Barclays 26th Annual Global Healthcare Conference
Format: Fireside Chat
Date: March 14, 2024
A live audio webcast of the Oppenheimer presentation can be accessed through the Investors section of the Company’s website at https://investors.orchestrabiomed.com/news-events/events. An archived replay of the webcast will be available on the Company’s website for 90 days following the live event.
About Orchestra BioMed
Forward-Looking Statements
Certain statements included in this press release that are not historical facts are forward-looking statements for purposes of the safe harbor provisions under the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements generally are accompanied by words such as “believe,” “may,” “will,” “estimate,” “continue,” “anticipate,” “intend,” “expect,” “should,” “would,” “plan,” “predict,” “potential,” “seem,” “seek,” “future,” “outlook” and similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These forward-looking statements include, but are not limited to, statements relating to the potential efficacy and safety of the Company’s commercial product candidates, the ability of the Company’s partnerships to accelerate clinical development, and the Company’s late-stage development programs, strategic partnerships and plans to expand its product pipeline. These statements are based on various assumptions, whether or not identified in this press release, and on the current expectations of the Company’s management and are not predictions of actual performance. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as and must not be relied on as a guarantee, an assurance, a prediction, or a definitive statement of fact or probability. Actual events and circumstances are difficult or impossible to predict and may differ from assumptions. Many actual events and circumstances are beyond the control of the Company. These forward-looking statements are subject to a number of risks and uncertainties, including changes in domestic and foreign business, market, financial, political, and legal conditions; risks related to regulatory approval of the Company’s product candidates and ongoing regulation of the Company’s product candidates, if approved; the timing of, and the Company’s ability to achieve, expected regulatory and business milestones; the impact of competitive products and product candidates; and the risk factors discussed under the heading “Item 1A. Risk Factors” in the Company’s quarterly report on Form 10-Q filed with the U.S. Securities and Exchange Commission on May 12, 2023, as updated by any risk factors disclosed under the heading “Item 1A. Risk Factors” in the Company’s subsequently filed quarterly reports on Form 10-Q.
The Company operates in a very competitive and rapidly changing environment. New risks emerge from time to time. Given these risks and uncertainties, the Company cautions against placing undue reliance on these forward-looking statements, which only speak as of the date of this press release. The Company does not plan and undertakes no obligation to update any of the forward-looking statements made herein, except as required by law.
References to Websites and Social Media Platforms
References to information included on, or accessible through, websites and social media platforms do not constitute incorporation by reference of the information contained at or available through such websites or social media platforms, and you should not consider such information to be part of this press release.

Frequently Asked Questions

When will Orchestra BioMed present at the Oppenheimer conference?

Orchestra BioMed will present at the Oppenheimer conference on March 12, 2024.

How can I access the Oppenheimer presentation webcast?

The Oppenheimer presentation can be accessed via their Investors section on the Company’s website.

What is the format of the Barclays conference presentation?

The format for the Barclays conference will be a fireside chat on March 14, 2024.

What kinds of statements are included in this press release?

The press release includes forward-looking statements regarding future events and trends.

Where can I find risk factors related to Orchestra BioMed?

Risk factors are detailed in the Company's quarterly report on Form 10-Q filed with the SEC.

Last updated: Mar 7, 2024